Quick Answer
Adaptive Biotechnologies Corp reported Long-Term Debt of $126.57 million for fiscal year 2025.
Adaptive Biotechnologies Corp Long-Term Debt — Annual History
| Fiscal Year | Long-Term Debt | YoY Change |
|---|---|---|
| 2025 | $126.57M | -4.4% |
| 2024 | $132.41M | +1.3% |
| 2023 | $130.66M | +4.2% |
| 2022 | $125.36M | — |
Quarterly Long-Term Debt
| Quarter Ending | Long-Term Debt | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $129.41M | -2.5% | -0.8% |
| June 30, 2025 | $130.50M | -1.2% | -0.8% |
| March 31, 2025 | $131.55M | +0.0% | -0.7% |
| December 31, 2024 | $132.41M | +1.3% | -0.2% |
| September 30, 2024 | $132.70M | +4.7% | +0.5% |
| June 30, 2024 | $132.08M | — | +0.4% |
| March 31, 2024 | $131.54M | — | +0.7% |
| December 31, 2023 | $130.66M | +4.2% | +3.1% |
- Adaptive Biotechnologies Corp showed a decrease of -4.4% in Long-Term Debt compared to the prior fiscal year.
- Over the 2022–2025 period, Adaptive Biotechnologies Corp’s long-term debt has grown by 1.0% (from $125.36 million to $126.57 million).
- The most recent figure is from Adaptive Biotechnologies Corp’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: